Boston Scientific Corporation (BSX) Receives ‘Analyst’ Rating

Boston Scientific Corporation (BSX) : The consensus on Boston Scientific Corporation (BSX) based on 20 analyst recommendation on the company stock is 1.63, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 analyst believes that the stock is a Buy, which can produce decent returns in the future. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Boston Scientific Corporation (BSX) : Currently there are 18 street experts covering Boston Scientific Corporation (BSX) stock. The most bullish and bearish price target for the stock is $30 and $20 respectively for the short term. The average price target of all the analysts comes to $26.08. The estimated standard deviation from the target is $2.99.


Also, Equity Analysts at the Brokerage Firm, Argus Research, upgrades their rating on the shares of Boston Scientific Corporation (NYSE:BSX). Argus Research has a Buy rating on the shares. Previously, the analysts had a Hold rating on the shares. As per the latest report, the brokerage house announces the price target to $33 per share. The rating by the firm was issued on September 1, 2016.

Boston Scientific Corporation (NYSE:BSX): After opening at $23.15, the stock dipped to an intraday low of $23.14 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $23.77 and the buying power remained strong till the end. The stock closed at $23.62 for the day, a gain of 2.21% for the day session. The total traded volume was 13,201,247. The stocks close on the previous trading day was $23.11.

Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.